EA202190810A1 - Способы и наборы для получения цельной крови с инактивированным патогеном - Google Patents

Способы и наборы для получения цельной крови с инактивированным патогеном

Info

Publication number
EA202190810A1
EA202190810A1 EA202190810A EA202190810A EA202190810A1 EA 202190810 A1 EA202190810 A1 EA 202190810A1 EA 202190810 A EA202190810 A EA 202190810A EA 202190810 A EA202190810 A EA 202190810A EA 202190810 A1 EA202190810 A1 EA 202190810A1
Authority
EA
Eurasian Patent Office
Prior art keywords
kits
methods
whole blood
inactivated pathogen
obtaining whole
Prior art date
Application number
EA202190810A
Other languages
English (en)
Inventor
Гарри Кэхайэди
Энн Норт
Мелисса Фон Гетц
Анна Эриксон
Original Assignee
Сирус Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сирус Корпорейшн filed Critical Сирус Корпорейшн
Publication of EA202190810A1 publication Critical patent/EA202190810A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0281—Apparatus for treatment of blood or blood constituents prior to transfusion, e.g. washing, filtering or thawing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0209—Multiple bag systems for separating or storing blood components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20—Targets to be treated
    • A61L2202/22—Blood or products thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к способам получения цельной крови с инактивированным патогеном и к другим композициям продуктов крови с инактивированным патогеном, а также к наборам и к родственным композициям.
EA202190810A 2018-09-20 2019-09-20 Способы и наборы для получения цельной крови с инактивированным патогеном EA202190810A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862734117P 2018-09-20 2018-09-20
PCT/US2019/052286 WO2020061537A1 (en) 2018-09-20 2019-09-20 Methods and kits for preparing pathogen-inactivated whole blood

Publications (1)

Publication Number Publication Date
EA202190810A1 true EA202190810A1 (ru) 2021-08-23

Family

ID=68165717

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190810A EA202190810A1 (ru) 2018-09-20 2019-09-20 Способы и наборы для получения цельной крови с инактивированным патогеном

Country Status (8)

Country Link
US (1) US20220031917A1 (ru)
EP (1) EP3852817A1 (ru)
CN (1) CN113271975A (ru)
CA (1) CA3113655A1 (ru)
EA (1) EA202190810A1 (ru)
IL (1) IL281504B1 (ru)
MX (1) MX2021003180A (ru)
WO (1) WO2020061537A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019010492A (es) 2017-03-03 2019-11-25 Cerus Corp Kits y metodos para preparar composiciones de plaquetas con patogeno inactivado.
EA202091602A1 (ru) 2017-12-29 2020-10-19 Сирус Корпорейшн Системы и способы для обработки биологических жидкостей
JP2022537457A (ja) 2019-06-22 2022-08-25 シーラス コーポレイション 生物学的流体処理システム
CN114269394A (zh) 2019-06-28 2022-04-01 塞鲁斯公司 用于实现生物流体处理装置的***和方法
FR3133135A1 (fr) * 2022-03-04 2023-09-08 Maco Pharma Système à poches pour le traitement par irradiation électromagnétique d’un fluide biologique

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691132A (en) 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
US6136586A (en) 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
US6514987B1 (en) 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
US6093725A (en) 1997-01-06 2000-07-25 Cerus Corporation Frangible compounds for pathogen inactivation
US6093564A (en) 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
EP1045704B1 (en) * 1998-01-06 2004-09-22 Cerus Corporation Methods for quenching pathogen inactivators in biological materials
US7025877B1 (en) 1999-06-03 2006-04-11 Baxter International Inc. Processing set for processing and treating a biological fluid
US20020042043A1 (en) * 2000-05-31 2002-04-11 Adonis Stassinopoulos Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity
EP1365750A2 (en) * 2000-12-21 2003-12-03 Cerus Corporation Methods for inactivation of pathogens in biological materials
CA2477946A1 (en) 2002-03-14 2003-09-25 Baxter International Inc. Compound removal device
CN103961731B (zh) * 2004-10-29 2017-01-18 塞鲁斯公司 用于红细胞灭活过程的改进的猝灭方法
WO2009026073A1 (en) * 2007-08-22 2009-02-26 Caridianbct Biotechnologies, Llc Prevention of transfusion related acute lung injury using riboflavin and light
BRPI0911176B8 (pt) * 2008-04-09 2021-05-25 Cerus Corp método de tratar uma composição de célula vermelha sanguínea, composição de célula vermelha sanguínea, e método de reduzir a desidratação em uma composição de célula vermelha sanguínea
WO2018125994A1 (en) * 2016-12-31 2018-07-05 Cerus Corporation Compositions and methods for preparation of red blood cells
JP2021533185A (ja) * 2018-07-27 2021-12-02 ザタ ファーマシューティカルズ，インコーポレイティド 病原体、微生物及び寄生虫を不活化させる方法

Also Published As

Publication number Publication date
MX2021003180A (es) 2021-05-14
IL281504A (en) 2021-04-29
WO2020061537A1 (en) 2020-03-26
EP3852817A1 (en) 2021-07-28
CA3113655A1 (en) 2020-03-26
IL281504B1 (en) 2024-04-01
CN113271975A (zh) 2021-08-17
US20220031917A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
EA202190810A1 (ru) Способы и наборы для получения цельной крови с инактивированным патогеном
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
TR201901445T4 (tr) Il2rbeta/yaygın gamma zinciri antikorları.
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201892147A1 (ru) Бициклические соединения
EA201592074A1 (ru) Композиции и способы изменения сигнальной системы вторичного мессенджера
EA201790413A1 (ru) Антитела против tigit
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
EA202090720A1 (ru) ПРОИЗВОДНЫЕ GalNAc
EA201890247A1 (ru) Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин
CY1123263T1 (el) Πολυκυκλικες ενωσεις ως αναστολεις κινασης τυροσινης bruton
EA201691541A1 (ru) Новые анти-baff антитела
EA201991798A1 (ru) Стабильные при хранении составы
EA201892716A1 (ru) Антитела к фактору свертывания xi
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201890572A1 (ru) Биофармацевтические композиции
EA201892500A1 (ru) Применение фракции лигнина в качестве антифитопатогенного агента и содержащие ее антифитопатогенные композиции
EA202092849A1 (ru) Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
EA201990998A1 (ru) Фармацевтические составы и способы их получения
EA202091259A1 (ru) Способ получения опикапона и его интермедиатов
EA202192786A1 (ru) Твердые формы (e)-3-[2-(2-тиенил)винил]-1h-пиразола
EA201992302A1 (ru) Соединения, используемые в качестве ингибиторов alcat1
EA202091471A1 (ru) Полиморфы